CY3

$50.60

Category: Weight Loss
Package: 100 pills
Manufacturer: Dragon Pharma
Substance: Clenbuterol hydrochloride (Clen), Liothyronine (T3), Yohimbine

Out of stock

SKU: 774 Category:

Description

Dragon Pharma produces CY3, an oral drug for sale in our store containing Liothyronine Sodium, Clenbuterol Hydrochloride, and Yohimbine Hydrochloride. Each CY3 tablet contains 37mcg of Clenbuterol, 25mcg of Liothyronine, and 5.4mg of Yohimbine, all of which are stimulants that work together to help people lose weight quickly. Because they have varying absorption rates and bioavailability, these three stimulants perform incredibly well together. Each of these stimulants are sold separately and are effective when used alone; but, when they are combined, the benefits are significantly enhanced.

Liothyronine also helps to shred a lot of fat, allowing the muscles to expand. As a result, combining these three generates a potent dose for those who are overweight to lose fat quickly and effectively.

Effects of CY3

The use of CY3 offers the same benefits of using three powerful fat burning steroids, such as:

  • Boost Athletic Performance
  • Boosts the Process of Thermogenesis
  • Prompts Lipolysis Effect
  • Increased Heart Rate and Blood Flow
  • Excellent Fat Burner
  • Increases Metabolism
  • Develop Muscle Mass
  • Enhance Body Strength
  • Weight Loss
  • Treats Erectile Dysfunction

A CY3 cycle

The suggested CY3 dosage is determined by a variety of factors, including your body’s unique traits. Because the half-life is around 10 hours, a typical starting dosage for men and women is 1 pill per day. It is recommended that you take CY3 daily for two weeks and then take two weeks off, but you should not use the drug for more than eight weeks because it can create undesired side effects. Before beginning any cycle, rookie athletes should get advice from a professional.

Additional information

Brand

Package

Substance

Reviews

There are no reviews yet.

Be the first to review “CY3”

Your email address will not be published.